Next‐Generation Preclinical Functional Testing Models in Cancer Precision Medicine: CTC‐Derived Organoids
Small Methods · 2024
DOI: 10.1002/smtd.202301009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small Methods, 2024. Verfasst von Lanxiang Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: Science Fund for Creative Research Groups of the Natural Science Foundation of Hubei Province, medical Sci-Tech innovation platform of Zhongnan Hospital, Medical Top-talented youth development project of Hubei Province and Clinical research transformation project of Zhongnan Hospital.
Abstract (Originalsprache)
Basic and clinical cancer research requires tumor models that consistently recapitulate the characteristics of prima tumors. As ex vivo 3D cultures of patient tumor cells, patient‐derived tumor organoids possess the biological properties of primary tumors and are therefore excellent preclinical models for cancer research. Patient‐derived organoids can be established using primary tumor tissues, peripheral blood, pleural fluid, ascites, and other samples containing tumor cells. Circulating tumor cells acquired by non‐invasive sampling feature dynamic circulation and high heterogeneity. Circulating tumor cell‐derived organoids are prospective tools for the dynamic monitoring of tumor mutation evolution profiles because they reflect the heterogeneity of the original tumors to a certain extent. This review discusses the advantages and applications of patient‐derived organoids. Meanwhile, this work highlights the biological functions of circulating tumor cells, the latest advancement in research of circulating tumor cell‐derived organoids, and potential application and challenges of this technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- Center for Single-Cell Omics and Tumor Liquid Biopsy, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Wuhan, 430071, China.
- Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, 430071, China.
ORCID-Profile: Fubing Wang
Förderung
- Science Fund for Creative Research Groups of the Natural Science Foundation of Hubei Province
- medical Sci-Tech innovation platform of Zhongnan Hospital
- Medical Top-talented youth development project of Hubei Province and Clinical research transformation project of Zhongnan Hospital
- National Natural Science Foundation of China
- Basic and Clinical Medical Research Joint Fund of Zhongnan Hospital of Wuhan University
Zitieren
APA
Huang, L., Xu, Y., Wang, N., Yi, K., Xi, X., Si, H., Zhang, Q., Xiang, M., Rong, Y., Yuan, Y., & Wang, F. (2024). Next‐Generation Preclinical Functional Testing Models in Cancer Precision Medicine: CTC‐Derived Organoids. Small Methods. https://doi.org/10.1002/smtd.202301009
Vancouver
Huang L, Xu Y, Wang N, Yi K, Xi X, Si H, et al. Next‐Generation Preclinical Functional Testing Models in Cancer Precision Medicine: CTC‐Derived Organoids. Small Methods. 2024. doi:10.1002/smtd.202301009
BibTeX
@article{Huang2024,
author = {Huang, Lanxiang and Xu, Yaqi and Wang, Na and Yi, Kezhen and Xi, Xiaodan and Si, Huaqi and Zhang, Qian and Xiang, Ming and Rong, Yuan and Yuan, Yufeng and Wang, Fubing},
title = {Next‐Generation Preclinical Functional Testing Models in Cancer Precision Medicine: CTC‐Derived Organoids},
journal = {Small Methods},
year = {2024},
doi = {10.1002/smtd.202301009}
}
EUVIMED